---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002329"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:28.736257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b

## Summary
- 67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
- In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.
- Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.
- Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.
- Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU.

## SEC filing metadata
- accession: 0001213900-26-002329
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/0001213900-26-002329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/ea0272248-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002329
- JSON: https://secwatch.observer/filing/0001213900-26-002329.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.